ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADMA ADMA Biologics

Trading 02-23 09:35:28 EST

16.24

+0.14

+0.87%

High16.27	Low15.89	Vol29.54K
Open16.06	D1 Closing16.10	Amplitude2.35%
Mkt Cap3.87B	Tradable Cap3.80B	Total Shares238.00M
T/O474.60K	T/O Rate0.01%	Tradable Shares233.86M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADMA","market":"US","secType":"STK","nameCN":"ADMA Biologics","latestPrice":16.24,"timestamp":1771857324703,"preClose":16.1,"halted":0,"volume":29544,"delay":0,"changeRate":0.008695652173912858,"floatShares":233862209,"shares":237997765,"eps":0.855978,"marketStatus":"Trading","change":0.14,"latestTime":"02-23 09:35:28 EST","open":16.06,"high":16.265,"low":15.8874,"amount":474595.46596800006,"amplitude":0.023453,"askPrice":16.37,"askSize":300,"bidPrice":16.1,"bidSize":11,"shortable":3,"etf":0,"ttmEps":0.855978,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":16.1,"preHourTrading":{"tag":"盘前","latestPrice":16.12,"preClose":16.1,"latestTime":"09:15 EST","volume":237,"amount":3818.010039,"timestamp":1771856128200,"change":0.02,"changeRate":0.001242,"amplitude":0.035404},"postHourTrading":{"tag":"盘后","latestPrice":16.1,"preClose":16.1,"latestTime":"18:38 EST","volume":226974,"amount":3654283.4854,"timestamp":1771630682180,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.699295,"impliedVol":0.7995,"impliedVolPercentile":0.8725},"requestUrl":"/m/hq/s/ADMA/wiki","defaultTab":"wiki","newsList":[{"id":"2612446612","title":"ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446612","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446612?lang=en_us&edition=fundamental","pubTime":"2026-02-18 20:00","pubTimestamp":1771416000,"startTime":"0","endTime":"0","summary":"Conference Call Scheduled for February 25, 2026, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., Feb.  18, 2026  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240055/33130/en/ADMA-Biologics-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-25-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA","BK4141","LU1878469433.USD","PI"],"gpt_icon":0},{"id":"2612973624","title":"ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612973624","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612973624?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:40","pubTimestamp":1771382418,"startTime":"0","endTime":"0","summary":"Adam S. Grossman, President and CEO of ADMA Biologics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL6ZlynS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2602510485","title":"GUIDANCE: (ADMA) ADMA Biologics Expects 2026 Total Revenue About $635M, vs. FactSet Est of $631.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510485","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510485?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:12","pubTimestamp":1768223552,"startTime":"0","endTime":"0","summary":"GUIDANCE: (ADMA) ADMA Biologics Expects 2026 Total Revenue About $635M, vs. FactSet Est of $631.9M","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSS","ADMA"],"gpt_icon":0},{"id":"2602170055","title":"ADMA Biologics posts FY 2025 revenue of USD 510 million and year-end cash of USD 88 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2602170055","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602170055?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222843,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc. reported preliminary unaudited full year  2025 total revenue of approximately USD 510-511 million. Year-end 2025 cash holdings grew to around USD 88 million, with an estimated operating cash flow of about USD 40 million generated in the fourth quarter  of 2025. The company reiterated its guidance for FY 2025 adjusted EBITDA and adjusted net income. ADMA Biologics Inc. expects FY 2026 and FY 2027 revenue to reach approximately USD 635 million and USD 775 million, respectively. Adjusted net income is projected at around USD 255 million in FY 2026 and USD 315 million in FY 2027. Adjusted EBITDA is forecasted to be about USD 360 million in FY 2026 and USD 455 million in FY 2027. The company maintains its long-term target of generating over USD 1.1 billion in annual revenue and more than USD 700 million in adjusted EBITDA by FY 2029.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLcfXHW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","SG9999014039.USD","SG9999014013.SGD","ADMA","BK4588","LU2210150020.SGD","LU2095319765.USD","BK4139","SG9999014021.USD","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2602751058","title":"ADMA Biologics Inc - FY 2025 Preliminary Unaudited Total Revenue About $510-$511 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2602751058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602751058?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7JFQVY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2602510566","title":"ADMA Biologics Inc - Expects FY 2026 Revenue $635 Mln, FY 2027 $775 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510566","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510566?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7JFQVY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2602038517","title":"ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2602038517","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602038517?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7JFQVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2602177065","title":"ADMA Biologics Outlook FY Revenue USD 635 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2602177065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602177065?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222805,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nPLXEFAC6D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2601886635","title":"ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601886635","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601886635?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614400,"startTime":"0","endTime":"0","summary":"RAMSEY, N.J. and BOCA RATON, Fla., Jan.  05, 2026  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/05/3212592/33130/en/ADMA-Biologics-to-Present-at-the-J-P-Morgan-Healthcare-Conference-on-January-12-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0557290698.USD","LU0795875169.SGD","LU1791710582.SGD","LU0971096721.USD","XLV","BK4585","LU1732799900.SGD","BK4127","LU2111349929.HKD","BK4534","LU0029874061.USD","LU0225283273.USD","BK4139","BK4137","LU2347655156.SGD","LU0106831901.USD","LU1162221912.USD","LU1720051017.SGD","LU0314104364.USD","LU1791710400.SGD","LU2133065610.SGD","LABU","LU0098860793.USD","XBI","BK4504","LU2023251221.USD","LU0158827781.USD","ADMA","IE00BZ1G4Q59.USD","PI","BK4581","LU0158827948.USD","LU1548497426.USD","LU0882574139.USD","HCSG","LU1363072403.SGD","LU2089284900.SGD","LU2271345857.HKD","LU0320765646.SGD","LU0106261372.USD","LU0528227936.USD","LU1668664300.SGD","LU0267386448.USD","BK4588","LU1878469433.USD","LU0912757837.SGD","LU2357305700.SGD","BK4141","LU1074936037.SGD","LU0006306889.USD"],"gpt_icon":0},{"id":"2593412372","title":"The Bull Case For ADMA Biologics (ADMA) Could Change Following Its Higher 2025 Revenue Outlook Revision","url":"https://stock-news.laohu8.com/highlight/detail?id=2593412372","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593412372?lang=en_us&edition=fundamental","pubTime":"2025-12-23 22:15","pubTimestamp":1766499312,"startTime":"0","endTime":"0","summary":"Earlier in 2025, ADMA Biologics raised its 2025 revenue outlook to US$510 million, up from prior guidance of more than US$500 million, while modestly revising adjusted net income expectations to reflect a higher effective tax rate.\nThis updated guidance highlights management’s confidence in the performance of BIVIGAM and Nabi-HB and offers investors clearer visibility into the company’s near-term earnings profile.\nNext, we’ll explore how this higher 2025 revenue guidance refines ADMA...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/the-bull-case-for-adma-biologics-adma-could-change-following","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/the-bull-case-for-adma-biologics-adma-could-change-following","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADMA"],"gpt_icon":0},{"id":"2592952519","title":"ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592952519","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592952519?lang=en_us&edition=fundamental","pubTime":"2025-12-17 10:00","pubTimestamp":1765936857,"startTime":"0","endTime":"0","summary":"Adam S. Grossman, President and CEO of ADMA Biologics Inc., reported a disposal of common shares of ADMA Biologics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLb0frdf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2586261741","title":"ADMA Biologics (ADMA): Assessing Valuation as Short Interest Declines and Market Sentiment Improves","url":"https://stock-news.laohu8.com/highlight/detail?id=2586261741","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586261741?lang=en_us&edition=fundamental","pubTime":"2025-11-27 00:14","pubTimestamp":1764173662,"startTime":"0","endTime":"0","summary":"ADMA Biologics (ADMA) has seen its short interest drop by nearly 5% since the last report, now sitting at just under 9%. This is noticeably below the biotech's average peer short interest, which hovers above 14%.\nSee our latest analysis for ADMA Biologics.\nADMA Biologics has demonstrated impressive momentum lately, with its share price jumping 22.4% in the past week and 26.6% over the past month. While the total shareholder return over the past year is still in negative territory, the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-assessing-valuation-as-short-interest-de","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-assessing-valuation-as-short-interest-de","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2585030466","title":"High Growth Tech Stocks In The US For November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2585030466","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585030466?lang=en_us&edition=fundamental","pubTime":"2025-11-24 19:08","pubTimestamp":1763982486,"startTime":"0","endTime":"0","summary":"The U.S. stock market has recently experienced significant volatility, with major indices like the Nasdaq and S&P 500 posting substantial losses despite strong earnings reports from companies like Nvidia. This turbulent environment highlights the importance of identifying high-growth tech stocks that can withstand market fluctuations and capitalize on emerging trends, making them potentially attractive options for investors seeking growth opportunities in an unpredictable landscape.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/high-growth-tech-stocks-in-the-us-for-november-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/high-growth-tech-stocks-in-the-us-for-november-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4077","BK4023","BK4139","BK4613","ADMA","CLBT","CARG"],"gpt_icon":0},{"id":"2585120827","title":"ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585120827","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585120827?lang=en_us&edition=fundamental","pubTime":"2025-11-22 10:01","pubTimestamp":1763776876,"startTime":"0","endTime":"0","summary":"Adam S. Grossman, President and CEO of ADMA Biologics Inc., has reported a disposal of common shares of ADMA Biologics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251122:nNDL5Bjm6T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2581092641","title":"ADMA Biologics (ADMA) Receives a New Rating from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2581092641","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581092641?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:57","pubTimestamp":1762441040,"startTime":"0","endTime":"0","summary":"ADMA Biologics received a Buy rating and a $30.00 price target from Cantor Fitzgerald analyst Kristen Kluska yesterday. According to TipRanks, Klus...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/adma-biologics-adma-receives-a-new-rating-from-cantor-fitzgerald-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/adma-biologics-adma-receives-a-new-rating-from-cantor-fitzgerald-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADMA"],"gpt_icon":0},{"id":"2581826031","title":"ADMA Biologics Reports Strong Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581826031","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581826031?lang=en_us&edition=fundamental","pubTime":"2025-11-06 12:58","pubTimestamp":1762405122,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc ( ($ADMA) ) has released its Q3 earnings. Here is a breakdown of the information ADMA Biologics Inc presented to its investors. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adma-biologics-reports-strong-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adma-biologics-reports-strong-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"1126909388","title":"Stock Track | ADMA Biologics Plunges 5.72% After-Hours Despite Strong Q3 Results and Raised Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1126909388","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126909388?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:55","pubTimestamp":1762379705,"startTime":"0","endTime":"0","summary":"ADMA Biologics (NASDAQ:ADMA) shares tumbled 5.72% in after-hours trading on Wednesday, despite reporting better-than-expected third-quarter results and raising its full-year guidance. The sharp...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADMA"],"gpt_icon":0},{"id":"2581583701","title":"BRIEF-ADMA Biologics Q3 Revenue USD 134.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581583701","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581583701?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:06","pubTimestamp":1762376761,"startTime":"0","endTime":"0","summary":"BRIEF-ADMA Biologics Q3 Revenue USD 134.2 Million\n\n\nNov 05 (Reuters) - ADMA Biologics Q3 net income USD 36.4 million.\n\nQ3 adjusted EBITDA USD 58.7 million\nQ3 gross profit USD 75.6 million\nQ3 adjusted net income USD 38.9 million\noutlook FY revenue USD 510 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX27CE15:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2581083994","title":"ADMA Biologics Inc Outlook  2026 Total Revenue: Raised to at Least $630 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581083994","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581083994?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:05","pubTimestamp":1762376716,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX27CE15:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2581440701","title":"ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581440701","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581440701?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:05","pubTimestamp":1762376700,"startTime":"0","endTime":"0","summary":"3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase  3Q 2025 Adjusted EBITDA(1) of $58.7 Million, a 29% YoY Increase  3Q 2025 Adjust","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181938/33130/en/ADMA-Biologics-Announces-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4141","PI","BK4196","LU1878469433.USD","ADMA","AMS","IG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.admabiologics.com","stockEarnings":[{"period":"1week","weight":0.0006},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.0629},{"period":"6month","weight":-0.0955},{"period":"1year","weight":0.0012},{"period":"ytd","weight":-0.1173}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.021016},{"month":2,"riseRate":0.5,"avgChangeRate":-0.016157},{"month":3,"riseRate":0.636364,"avgChangeRate":0.108134},{"month":4,"riseRate":0.636364,"avgChangeRate":0.024806},{"month":5,"riseRate":0.636364,"avgChangeRate":0.053968},{"month":6,"riseRate":0.181818,"avgChangeRate":-0.056361},{"month":7,"riseRate":0.727273,"avgChangeRate":0.105206},{"month":8,"riseRate":0.272727,"avgChangeRate":0.003287},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.032166},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.041559},{"month":11,"riseRate":0.636364,"avgChangeRate":0.093715},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.060542}],"exchange":"NASDAQ","name":"ADMA Biologics","nameEN":"ADMA Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ADMA Biologics,ADMA,ADMA Biologics股票,ADMA Biologics股票老虎,ADMA Biologics股票老虎国际,ADMA Biologics行情,ADMA Biologics股票行情,ADMA Biologics股价,ADMA Biologics股市,ADMA Biologics股票价格,ADMA Biologics股票交易,ADMA Biologics股票购买,ADMA Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction